olaparib (Lynparza)
Jump to navigation
Jump to search
Indications
- advanced (treatment refractory) ovarian cancer*, fallopian tube cancer or peritoneal cancer with germline BRCA1 mutation or BRCA2 mutation whose disease has responded to platinum based chemotherapy only if:
- they have had >=3 courses of platinum based chemotherapy (NGC, NICE)
- seems to improve progression-free survival in patients with newly diagnosed advanced ovarian cancer#[5]
- metastatic breast cancer with BRCA mutation[4]
- metastatic androgen-insensitive prostate cancer[2][7][8]
* on list of drugs to avoid for treatment of ovarian cancer[3]
- has not been shown to prolong survival
# industry-sponsored study
Contraindications
Dosage
- tablets: 100 mg, 150 mg
Adverse effects
- anemia, neutropenia, leukopenia[4]
- fatigue, headache
- nausea, vomiting
- respiratory tract infections: nasopharyngitis, influenza
- dyspepsia, diarrhea, constipation, indigestion, decreased appetite
- arthralgia, myalgia)
- dysgeusia, stomatitis[4]
Laboratory
Mechanism of action
- inhibits poly ADP-ribose polymerase
Complications
More general terms
References
- ↑ FDA News Release. December 19, 2014 FDA approves Lynparza to treat advanced ovarian cancer First LDT companion diagnostic test also approved to identify appropriate patients http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm
- ↑ 2.0 2.1 Mateo J et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015 Oct 29; 373:1697 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26510020 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1506859
- ↑ 3.0 3.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
- ↑ 4.0 4.1 4.2 4.3 FDA News Release. January 12, 2018 FDA approves first treatment for breast cancer with a certain inherited genetic mutation. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm592347.htm
- ↑ 5.0 5.1 Moore K, Colombo N, Scambia G et al Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Eng J Med. Oct 21, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30345884 Free Article https://www.nejm.org/doi/full/10.1056/NEJMoa1810858
- ↑ Kaufman B, Shapira-Frommer R, Schmutzler RK et al Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25366685 Free PMC Article
- ↑ 7.0 7.1 de Bono J, Mateo J, Fizazi K et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020; 382:2091-2102. May 28. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32343890 https://www.nejm.org/doi/10.1056/NEJMoa1911440
- ↑ 8.0 8.1 Hussain M et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 2020 Sep 20; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32955174 https://www.nejm.org/doi/10.1056/NEJMoa2022485
- ↑ Medscape: olaparib (Rx) https://reference.medscape.com/drug/lynparza-olaparib-999934